Bororetinoids As Potential Therapeutics For Treatment Of Glioblastoma | 10577
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Glioblastoma multiforme (GBM), also simply called glioblastoma, is the most aggressive primary brain tumor in adults with
two-year survival rate of 28% following surgical resection, chemotherapy, and radiotherapy. Recurrence of gliobalstoma
is nearly certain after initial treatment and there is currently no therapy proven to prolong the survival of the patients after
tumor recurrence. Thus, there is a desperate need for new and improved therapies to combat growth and regrowth of GBM.
Retinoic acid (RA) signaling pathways regulate GBM stem cell biology, RA is used as chemotherapeutic agent, and also RA based
therapeutic agents penetrate blood-brain-barrier (BBB). RAs are a class of natural and synthetic vitamin A analogues that play
a central role in the control of cell growth and differentiation of normal and malignant cell types. Thus, retinoid therapy has the
potential to impact a wide array of disorders. Given the long history of research and major strides in understanding retinoid
biology, it is somewhat surprising and certainly frustrating that better probes and drugs are not available due to toxicity and lack
of specificity of the compounds to receptors. To address this issue, we have develop new chemistry to generate small libraries of
boron-containing retinoids and test their activity via reporter cell, whole animal, and embryonic stem cell based assays and tested
their anti-cancer mechanisms in different human glioblastoma cells lines. The overall goal of our program is to develop retinoid
based multifunctional therapeutic agents in other words ?single drug multitarget?, which will be useful not only to inhibits tumor
cells, but also will protect normal central nervous system (CNS) cells.
Bhaskar C. Das has completed his Ph.D. at the age of 28 years from Indian Institute of Technology (IIT), Kanpur (India) and postdoctoral studies from
UTK, Harvard Medical School and MIT. He is the Associate Professor of Internal Medicine of the University of Kansas Medical Center, a premier bio-
medical organization. He has published more than 50 papers in reputed journals and holds 12 patents. He is serving as an editorial board member
of repute and member of many national and international scientific organizations and scientific reviewer of many funding agencies.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals